Angiogenesis at the mold-host interface: A potential key to understanding and treating invasive aspergillosis

Future Microbiology

Volumn 8, Issue 11, 2013, Pages 1453-1462

  Ben Ami, Ronen ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

angiogenesis; FGF; gliotoxin; invasive aspergillosis; secondary metabolism; VEGF

Indexed keywords

AMPHOTERICIN B; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CD31 ANTIGEN; CORTISONE ACETATE; CYCLOPHOSPHAMIDE; ECHINOCANDIN; FIBROBLAST GROWTH FACTOR 2; GLIOTOXIN; POLYENE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; TRIAZOLE DERIVATIVE; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR; VORICONAZOLE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIFUNGAL ACTIVITY; ASPERGILLUS FUMIGATUS; DOWN REGULATION; DRUG DOSE INCREASE; DRUG EFFECT; ECOLOGICAL NICHE; EXTRACELLULAR MATRIX; FUNGAL GENE; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REPRESSION; HISTOPATHOLOGY; HUMAN; HYPOXEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INVASIVE ASPERGILLOSIS; LUNG ALVEOLUS MACROPHAGE; LUNG ASPERGILLOSIS; MICROENVIRONMENT; NEUTROPENIA; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VASCULAR DISEASE;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; HOST-PATHOGEN INTERACTIONS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84888246248     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.114     Document Type: Review

References (74)

1. Segal BH. Aspergillosis. N. Engl. J. Med. 360(18), 1870-1884 (2009).
2. Steinbach WJ, Marr KA, Anaissie EJ et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J. Infect. 65(5), 453-464 (2012).
3. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 44(10), 1289-1297 (2007). (Pubitemid 46717290)
4. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347(6), 408-415 (2002). (Pubitemid 34851833)
5. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42(5), 657-668 (2006). (Pubitemid 43271379)
6. Stergiopoulou T, Meletiadis J, Roilides E et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am. J. Clin. Pathol. 127(3), 349-355 (2007). (Pubitemid 46806327)
7. Lopes Bezerra L.M., Filler SG Interactions of Aspergillus fumigatus with endothelial cells: internalization, injury, and stimulation of tissue factor activity. Blood 103(6), 2143-2149 (2004). (Pubitemid 38326231)
8. Paterson PJ, Seaton S, Prentice H.G., Kibbler CC Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. J. Antimicrob. Chemother. 52(5), 873-876 (2003). (Pubitemid 37407821)
9. Ben-Ami R., Lewis RE, Leventakos K, Kontoyiannis DP Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood 114(26), 5393-5399 (2009).
10. Cooney NM, Klein BS Fungal adaptation to the mammalian host: it is a new world, after all. Curr. Opin. Microbiol. 11(6), 511-516 (2008).
11. Grahl N, Shepardson KM, Chung D, Cramer RA Hypoxia and fungal pathogenesis: to air or not to air? Eukaryot. Cell 11(5), 560-570 (2012).
12. Hall LA, Denning DW Oxygen requirements of Aspergillus species. J. Med. Microbiol. 41(5), 311-315 (1994). (Pubitemid 24353610)
13. Tabak H, Cooke W. The effect of gaseous environments on the growth and metabolism of fungi. Bot. Rev. 34, 126-252 (1968).
14. Ben-Ami R., Lewis RE, Kontoyiannis DP Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br. J. Haematol. 150 (4), 406-417 (2010).
15. Philippe B, Ibrahim-Granet O, Prevost MC et al. Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates. Infect. Immun. 71(6), 3034-3042 (2003). (Pubitemid 36637524)
16. Cornish EJ, Hurtgen BJ, McInnerney K et al. Reduced nicotinamide adenine dinucleotide phosphate oxidase-independent resistance to Aspergillus fumigatus in alveolar macrophages. J. Immunol. 180(10), 6854-6867 (2008).
17. Bonnett CR, Cornish EJ, Harmsen A.G., Burritt JB Early neutrophil recruitment and aggregation in the murine lung inhibit germination of Aspergillus fumigatus conidia. Infect. Immun. 74(12), 6528-6539 (2006). (Pubitemid 44913127)
18. Zarember KA, Sugui JA, Chang Y.C., Kwon-Chung KJ, Gallin JI Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion. J. Immunol. 178(10), 6367-6373 (2007). (Pubitemid 46717421)
19. Levitz SM, Farrell TP Human neutrophil degranulation stimulated by Aspergillus fumigatus. J. Leukoc. Biol. 47(2), 170-175 (1990). (Pubitemid 20061671)
20. Bruns S, Kniemeyer O, Hasenberg M et al. Production of extracellular traps against Aspergillus fumigatus in vitro and in infected lung tissue is dependent on invading neutrophils and influenced by hydrophobin RodA. PLoS Pathog. 6(4), e1000873 (2010).
21. Rankin NE. Disseminated aspergillosis and moniliasis associated with agranulocytosis and antibiotic therapy. Br. Med. J. 1(4816), 918-919 (1953).
22. Askew DS. Aspergillus fumigatus: virulence genes in a street-smart mold. Curr. Opin. Microbiol. 11(4), 331-337 (2008).
23. Rhodes JC, Oliver BG, Askew D.S., Amlung T W. Identification of genes of Aspergillus fumigatus up-regulated during growth on endothelial cells. Med. Mycol. 39(3), 253-260 (2001).
24. Gravelat FN, Ejzykowicz DE, Chiang LY et al. Aspergillus fumigatus MedA governs adherence, host cell interactions and virulence. Cell. Microbiol. 12(4), 473-488 (2010).
25. Chiang LY, Sheppard DC, Gravelat F.N., Patterson TF, Filler SG Aspergillus fumigatus stimulates leukocyte adhesion molecules and cytokine production by endothelial cells in vitro and during invasive pulmonary disease. Infect. Immun. 76(8), 3429-3438 (2008).
26. Curty N, Kubitschek-Barreira PH, Neves GW et al. Discovering the infectome of human endothelial cells challenged with the angioinvasive fungus Aspergillus fumigatus applying a high definition mass spectrometry label-free approach. J. Proteomics (2013) (In Press).
27. Balloy V, Huerre M, Latge J.P., Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect. Immun. 73(1), 494-503 (2005). (Pubitemid 40041144)
28. Berenguer J, Allende MC, Lee JW et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone- induced immunosuppression. Am. J. Respir. Crit. Care Med. 152(3), 1079-1086 (1995).
29. Grahl N, Puttikamonkul S, Macdonald JM et al. In vivo hypoxia and a fungal alcohol dehydrogenase influence the pathogenesis of invasive pulmonary aspergillosis. PLoS Pathog. 7(7), e1002145 (2011).
30. Willger SD, Puttikamonkul S, Kim KH et al. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog. 4(11), e1000200 (2008).
31. Carmeliet P, Jain RK Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347), 298-307 (2011).
32. Fraisl P, Mazzone M, Schmidt T., Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev. Cell 16(2), 167-179 (2009).
33. Oh IY, Yoon CH, Hur J et al. Involvement of E-selectin in recruitment of endothelial progenitor cells and angiogenesis in ischemic muscle. Blood 110(12), 3891-3899 (2007). (Pubitemid 350248444)
34. Yoshida S, Ono M, Shono T et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell. Biol. 17(7), 4015-4023 (1997). (Pubitemid 27281877)
35. Maulik N. Redox signaling of angiogenesis. Antioxid. Redox Signal. 4(5), 805-815 (2002). (Pubitemid 35246944)
36. Werth N, Beerlage C, Rosenberger C et al. Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens. PLoS ONE 5(7), e11576 (2010).
37. Kodama T, Shimizu N, Yoshikawa N et al. Role of the glucocorticoid receptor for regulation of hypoxia-dependent gene expression. J. Biol. Chem. 278(35), 33384-33391 (2003). (Pubitemid 37055791)
38. Keller NP, Turner G, Bennett J W. Fungal secondary metabolism - from biochemistry to genomics. Nat. Rev. Microbiol. 3(12), 937-947 (2005). (Pubitemid 43078157)
39. Lee HJ, Lee JH, Hwang B.Y., Kim HS, Lee JJ Anti-angiogenic activities of gliotoxin and its methylthioderivative, fungal metabolites. Arch. Pharm. Res. 24(5), 397-401 (2001). (Pubitemid 33647256)
40. Sin N, Meng L, Wang M.Q., Wen JJ, Bornmann WG, Crews CM The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, Met A P-2. Proc. Natl Acad. Sci. USA 94(12), 6099-6103 (1997). (Pubitemid 27270643)
41. Hayashi A, Arai M, Fujita M., Kobayashi M. Pyripyropenes, fungal sesquiterpenes conjugated with alpha-pyrone and pyridine moieties, exhibits anti-angiogenic activity against human umbilical vein endothelial cells. Biol. Pharm. Bull. 32(7), 1261-1265 (2009).
42. Arakawa M, Someno T, Kawada M., Ikeda D. A new terrein glucoside, a novel inhibitor of angiogenin secretion in tumor angiogenesis. J. Antibiot. (Tokyo) 61(7), 442-448 (2008).
43. Schwartz B, Shoseyov O, Melnikova VO et al. ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis. Cancer Res. 67(11), 5258-5266 (2007). (Pubitemid 46997264)
44. Nicholson B, Lloyd GK, Miller BR et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 17(1), 25-31 (2006).
45. Bok JW, Balajee SA, Marr KA et al. LaeA, a regulator of morphogenetic fungal virulence factors. Eukaryot. Cell 4 (9), 1574-1582 (2005). (Pubitemid 41339112)
46. Perrin RM, Fedorova ND, Bok JW et al. Transcriptional regulation of chemical diversity in Aspergillus fumigatus by LaeA. PLoS Pathog. 3(4), e50 (2007).
47. McDonagh A, Fedorova ND, Crabtree J et al. Sub-telomere directed gene expression during initiation of invasive aspergillosis. PLoS Pathog. 4(9), e1000154 (2008).
48. Murayama T, Amitani R, Ikegami Y., Nawada R, Lee WJ, Kuze F. Suppressive effects of Aspergillus fumigatus culture filtrates on human alveolar macrophages and polymorphonuclear leucocytes. Eur. Respir. J. 9(2), 293-300 (1996). (Pubitemid 26068624)
49. Mullbacher A, Waring P, Eichner RD Identification of an agent in cultures of Aspergillus fumigatus displaying anti-phagocytic and immunomodulating activity in vitro. J. Gen. Microbiol. 131(5), 1251-1258 (1985). (Pubitemid 15028300)
50. Tsunawaki S, Yoshida LS, Nishida S, Kobayashi T., Shimoyama T. Fungal metabolite gliotoxin inhibits assembly of the human respiratory burst NADPH oxidase. Infect. Immun. 72(6), 3373-3382 (2004). (Pubitemid 38697762)
51. Choi HS, Shim JS, Kim J.A., Kang SW, Kwon HJ Discovery of gliotoxin as a new small molecule targeting thioredoxin redox system. Biochem. Biophys. Res. Commun. 359(3), 523-528 (2007). (Pubitemid 46898983)
52. Kroll M, Arenzana-Seisdedos F, Bachelerie F., Thomas D, Friguet B, Conconi M. The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome Chem. Biol. 6(10), 689-698 (1999). (Pubitemid 29485531)
53. Suen YK, Fung KP, Lee C.Y., Kong SK Gliotoxin induces apoptosis in cultured macrophages via production of reactive oxygen species and cytochrome c release without mitochondrial depolarization. Free Radic. Res. 35(1), 1-10 (2001). (Pubitemid 32725620)
54. Waring P, Eichner RD, Mullbacher A, Sjaarda A. Gliotoxin induces apoptosis in macrophages unrelated to its antiphagocytic properties. J. Biol. Chem. 263(34), 18493-18499 (1988). (Pubitemid 19005126)
55. Lewis RE, Wiederhold NP, Chi J et al. Detection of gliotoxin in experimental and human aspergillosis. Infect. Immun. 73(1), 635-637 (2005). (Pubitemid 40041162)
56. Sugui JA, Pardo J, Chang YC et al. Gliotoxin is a virulence factor of Aspergillus fumigatus: gliP deletion attenuates virulence in mice immunosuppressed with hydrocortisone. Eukaryot. Cell 6 (9), 1562-1569 (2007). (Pubitemid 47483599)
57. Ben-Ami R., Albert ND, Lewis R.E., Kontoyiannis DP Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J. Infect. Dis. 207(7), 1066-1074 (2013).
58. Sau K, Mambula SS, Latz E, Henneke P., Golenbock DT, Levitz SM The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J. Biol. Chem. 278(39), 37561-37568 (2003). (Pubitemid 37175278)
59. Roilides E, Lyman CA, Filioti J et al. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob. Agents Chemother. 46(6), 1974-1976 (2002). (Pubitemid 34535224)
60. Cleary JD, Chapman SW, Nolan RL Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob. Agents Chemother. 36(5), 977-981 (1992).
61. Nagy JA, Feng D, Vasile E et al. Permeability properties of tumor surrogate blood vessels induced by VEGF-A. Lab. Invest. 86(8), 767-780 (2006). (Pubitemid 44100476)
62. Dvorak HF, Nagy JA, Feng D, Brown L.F., Dvorak AM Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237, 97-132 (1999). (Pubitemid 28554861)
63. Walters EH, Reid D, Soltani A., Ward C. Angiogenesis: a potentially critical part of remodelling in chronic airway diseases? Pharmacol. Ther. 118(1), 128-137 (2008).
64. Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect. Dis. Clin. North Am. 16(4), 875-894, vi (2002). (Pubitemid 35477517)
65. Inoue K, Matsuyama W, Hashiguchi T et al. Expression of vascular endothelial growth factor in pulmonary aspergilloma. Intern. Med. 40 (12), 1195-1199 (2001). (Pubitemid 34110496)
66. Dhillon GS, Zamora MR, Roos JE et al. Lung transplant airway hypoxia: a diathesis to fibrosis? Am. J. Respir. Crit. Care Med. 182(2), 230-236 (2010).
67. Babu AN, Murakawa T, Thurman JM et al. Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. J. Clin. Invest. 117(12), 3774-3785 (2007). (Pubitemid 350224088)
68. Jiang X, Hsu JL, Tian W et al. Tie2-dependent VHL knockdown promotes airway microvascular regeneration and attenuates invasive growth of Aspergillus fumigatus. J. Mol. Med. (Berl.) (2013) (In Press).
69. Snelders E, van der Lee HA, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5(11), e219 (2008).
70. Marr K, Schlamm H, Rottinghaus ST et al. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. Presented at: 22nd European Congress of Clinical Microbiology and Infectious Diseases. London, UK, 31 March-3 April 2012.
71. Ito JI. Enhancing angiogenesis in invasive aspergillosis: a novel therapeutic approach. J. Infect. Dis. 207(7), 1031-1033 (2013).
72. Trujillo A, McGee C, Cogle CR Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J. Oncol. 2012, 128608 (2012).
73. Casadevall A, Pirofski LA The damage - response framework of microbial pathogenesis. Nat. Rev. Microbiol. 1(1), 17-24 (2003).
74. Pikman R, Ben-Ami R. Immune modulators as adjuncts for the prevention and treatment of invasive fungal infections. Immunotherapy 4(12), 1869-1882 (2012).